Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer
| العنوان: | Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer |
|---|---|
| المؤلفون: | Bao-Jun Lv, Zhi-Hui Wang, Mei Xiao, Xiao-Lu Xu, Siyang Wang, Zhong Lin, Peijian Peng, Weize Lv |
| المصدر: | Translational Oncology Translational Oncology, Vol 12, Iss 4, Pp 656-660 (2019) |
| بيانات النشر: | Neoplasia Press, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Original article, Anemia, medicine.medical_treatment, Phases of clinical research, lcsh:RC254-282, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Medicine, Nedaplatin, Adverse effect, Chemotherapy, Leukopenia, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical trial, Regimen, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, medicine.symptom, business |
| الوصف: | The platinum-based, two-drug, 3-week regimen is currently the main first-line chemotherapy program for the treatment of advanced squamous cell lung cancer. The aim of this phase II clinical study was to evaluate the efficacy and adverse events of the bi-weekly program of liposomal paclitaxel combined with nedaplatin as a first-line treatment for advanced squamous cell lung cancer. A total of 52 cases of advanced squamous cell lung cancer were included in this phase II clinical trial. Patients received intravenous infusion of liposomal paclitaxel (100 mg/m2) and nedaplatin (50 mg/m2) on days 1 and 15 of a 4-week cycle. Each patient received two to six cycles of chemotherapy, consistent with the regimen of combined liposomal paclitaxel and nedaplatin. The total effective rate of this chemotherapy program was 37.5%. The median progression-free survival time was 8.5 months (95% confidence interval: 7.8-9.2). The median survival time was 16 months (95% confidence interval: 14.1-17.9). The main adverse event was myelosuppression. Grade 3 leukopenia was noted in seven patients (13.5%), and no grade 4 leukopenia was observed. Grade 3 anemia was noted in four patients (7.7%), and no grade 4 anemia was observed. In addition, no grade 2 or higher thrombocytopenia and no grade 3 or 4 non-bone marrow toxicity was detected. The bi-weekly program of liposomal paclitaxel combined with nedaplatin is effective for the treatment of advanced squamous cell lung cancer, with high safety and few adverse events. However, additional studies are warranted to confirm these results. The trial was registered under the number ChiCTR-OIN-17011423. |
| اللغة: | English |
| تدمد: | 1936-5233 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486bd46bfb035ada41e921fc4db57d5a http://europepmc.org/articles/PMC6395851 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....486bd46bfb035ada41e921fc4db57d5a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19365233 |
|---|